FDA Approves Landmark Pancreatic Cancer Drug Showing Survival Improvements

Against one of medicine's most stubborn adversaries, the FDA has granted approval to a new pancreatic cancer treatment that measurably extends survival for patients who have long faced a diagnosis carrying the weight of finality. Pancreatic cancer has resisted progress for decades — silent in its early stages, aggressive in its spread, and modest in its response to conventional therapies — leaving patients and physicians with few meaningful choices. This approval does not promise a cure, but it shifts the horizon in a disease where even small movements forward represent hard-won victories for